Clinical Trial Update: Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study of dexamethasone, elotuzumab, and pomalidomide in patients with refractory multiple myeloma; the trial has completed and results were posted on 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Refractory Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2025-06-24